• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    (Problem) To provide a prophylactic or therapeutic agent for glaucoma. (Solution) A prophylactic or therapeutic agent for glaucoma containing an angiotensin II antagonist and at least one compound selected from an adrenergic receptor blocker, prostaglandins and carbonic anhydrase inhibitors simultaneously, separately or sequentially.
    公开号:KR20040045029A
    申请号:KR10-2004-7004652
    申请日:2000-12-01
    公开日:2004-05-31
    发明作者:요꼬야마도미히사
    申请人:상꾜 가부시키가이샤；
    IPC主号:
    专利说明:

    Combination of angiotensin II antagonists and adrenergic receptor blockers for the treatment of glaucoma {COMBINED ANGIOTENSIN II ANTAGONISTS AND ADRENALINE RECEPTOR BLOCKERS FOR TREATMENT OF GLAUCOMA}
    [1] The present invention relates to a glaucoma preventive or therapeutic agent having an excellent intraocular pressure lowering action.
    [2] Currently, β-blockers (maleic acid maleol, carteol, etc.), prostaglandin-type compounds (isopropyl unoprostone and latanoprost) and carbonic anhydrase inhibitors (dorzolamide hydrochloride) are mainly used as glaucoma therapeutic agents. α-blockers (bunazosin hydrochloride) and α-blockers (nipradilol) are in the phase of clinical trial or application for approval.
    [3] There is information that angiotensin II antagonists are useful as therapeutic agents for glaucoma (eg, EP795326, EP631780, WO95 / 21609, WO91 / 15206, etc.). CGP-48933, the only angiotensin II antagonist, has been clinically tested for a long time, but reports of insufficient effects on glaucoma (Eur-J-Ophthalmol. 1997 Jan-Mar; 7 (1): 35-9) Since then, development has not proceeded.
    [4] Disclosure of the Invention
    [5] The present inventors have diligently studied the preparation and pharmacological action of a prophylactic or therapeutic agent for glaucoma having an excellent hypotension effect, and as a result, one or more compounds selected from angiotensin II antagonists, adrenergic receptor blockers, prostaglandins and carbonic anhydrase inhibitors The present invention has been completed by discovering that intraocular pressure-lowering action is enhanced by using in combination.
    [6] The present invention,
    [7] (1) A prophylactic or therapeutic agent for glaucoma containing an angiotensin II antagonist and at least one compound selected from an adrenaline receptor blocker, prostaglandins and carbonic anhydrase inhibitors as an active ingredient for simultaneous, separate or sequential use.
    [8] Especially preferably in the above
    [9] (2) A prophylactic or therapeutic agent for glaucoma, wherein the angiotensin II antagonist is a compound having the formula (1) or a pharmacologically acceptable salt, ester or other derivative thereof:
    [10]
    [11] [Wherein, R 1 represents the following structural formulas (1a), (1b), (1c), (1d), (1e) or (1f):
    [12]
    [13] Represents a group having;
    [14] (3) the prophylactic or therapeutic agent for glaucoma in (2), wherein R 1 is a group having (1a), (1b) or (1c),
    [15] (4) the prophylactic or therapeutic agent for glaucoma in (2), wherein R 1 has (1a),
    [16] (5) a prophylactic or therapeutic agent for glaucoma, wherein the adrenaline receptor blocker is bunazosine, timolol, nipradilol or a pharmacologically acceptable salt or ester thereof;
    [17] (6) a prophylactic or therapeutic agent for glaucoma, wherein the adrenergic receptor blocker is bunazosine hydrochloride, timolol maleic acid or nipradilol;
    [18] (7) a prophylactic or therapeutic agent for glaucoma containing an angiotensin II antagonist and one or more compounds selected from prostaglandins and carbonic anhydrase inhibitors as active ingredients for use simultaneously, separately or sequentially;
    [19] (8) preventive or therapeutic agents for glaucoma, wherein the prostaglandins are isopropyl unoprostone, latanoprost or pharmacologically acceptable salts thereof;
    [20] (9) a prophylactic or preventive agent for glaucoma, wherein the prostaglandins are isopropyl unoprostone or latanoprost;
    [21] (10) a prophylactic or therapeutic agent for glaucoma, wherein the carbonic anhydrase inhibitor is dorzolamide or a pharmacologically acceptable salt thereof;
    [22] (11) a prophylactic or therapeutic agent for glaucoma wherein the carbonic anhydrase inhibitor is dorzolamide hydrochloride, and
    [23] (12) The prophylactic or therapeutic agent for glaucoma according to any one of (1) to (11), which is a shape suitable for topical administration to the eye.
    [24] In addition, the present invention,
    [25] (13) A method for preventing or treating glaucoma, comprising administering the prophylactic or therapeutic agent for glaucoma according to any one of (1) to (11).
    [26] In the present invention,
    [27] "Angiotensin II antagonist" refers to a compound that antagonizes angiotensin II at the angiotensin II receptor to reduce the action of angiotensin II. Preferably a compound that inhibits the function of angiotensin II by 50% or more at a concentration of 1 μM, more preferably angiotensin II selective antagonist. In particular, preferably "Angiotensin II antagonist" includes a compound having the formula (1) or a pharmacologically acceptable salt, ester or other derivative thereof:
    [28] [Formula 1]
    [29]
    [30] [Wherein, R 1 represents the following structural formulas (1a), (1b), (1c), (Id), (Ie) or (If):
    [31]
    [32] Represents a group having;
    [33] In the compound having the formula (1), preferably a compound in which R 1 is a group having (1a), (1b) or (1c), and particularly preferably a compound in which R 1 is a group having (1a).
    [34] The "adrenergic receptor blocker" refers to an α blocker, a β blocker or an α β blocker. The α-blocking agent preferably represents an α-blocking agent, particularly preferably bundazosin or a pharmacologically dissolved salt thereof, and most preferably bunazocin hydrochloride. The β-blocker particularly preferably represents timolol or a pharmacologically acceptable salt or ester thereof, most preferably timolol. [alpha] [beta] blocking agent particularly preferably represents nipradilol or a pharmacologically acceptable salt or ester thereof, and most preferably nipradilol.
    [35] "Prostaglandins" are prostaglandins that exist in nature such as prostaglandin F2α; Or derivatives of prostaglandins such as isopropyl unoprostone and latanoprost; Or pharmacologically acceptable salts thereof, particularly preferably isopropyl unoprostone and latanoprost or pharmacologically acceptable salts thereof, and most preferably isopropyl unoprostone and latanoprost.
    [36] "Carbohydrate dehydratase inhibitor" particularly preferably refers to dorzolamide or a pharmacologically acceptable salt thereof, and most preferably torazole amide hydrochloride.
    [37] "Pharmaceutically acceptable salt" means that the "angiotensin II antagonist", "adrenaline receptor blocker", "prostaglandins" and / or "carbonic anhydrase inhibitor" have an acidic group such as a carboxyl group, or a basic group such as an amino group or an imino group. Salts that may be formed when they are present.
    [38] As a salt based on an acidic group, Preferably, metal salts, such as alkali metal salts, such as a sodium salt, potassium salt, a lithium salt, alkaline earth metal salts, such as a calcium salt and a magnesium salt, aluminum salt, iron salt; Inorganic salts such as ammonium salt, t-octylamine salt, dibenzylamine salt, morpholine salt, glucosamine salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucamine salt, guanidine salt, diethylamine salt, tri Ethylamine salt, dicyclohexylamine salt, N, N'-dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine salt, N-benzylphenethylamine salt, piperazine salt, tetramethylammonium salt And amine salts such as organic salts such as tris (hydroxymethyl) aminomethane salts, and amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamate salts, and asparagine salts.
    [39] On the other hand, salts based on basic groups include, for example, inorganic acid salts such as hydrofluoric acid salts such as hydrofluoric acid salts, hydrochloride salts, hydrobromide salts and hydroiodic salts, nitrate salts, perchlorate salts, sulfate salts and phosphates; Lower alkanesulfonates such as methane sulfonate, trifluoromethane sulfonate, ethane sulfonate, benzene sulfonate, aryl sulfonates such as p-toluene sulfonate, acetate, malate, fumarate, succinate, citrate Organic acid salts such as ascorbate, tartarate, oxalate, maleate and the like; And amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamate salts, and asparagine salts.
    [40] In addition, said "pharmacologically acceptable salt" may absorb water by leaving in air or recrystallization, and water may adsorb | suck or become a hydrate, and such a hydrate is also contained in this invention.
    [41] An "ester or other derivative" is a compound obtained by modifying a functional group (for example, a hydroxyl group, a carboxyl group, an amino group, etc.) possessed by the "angiotensin II antagonist" with a protecting group according to a conventional method, and is administered to a living body by "administering an angiotensin II antagonist". To derivatives. The presence or absence of such derivatives can be determined by instillation, intravenous or oral administration of the compound to experimental animals such as rats or mice, and then by examining the animal liquor to confirm the angiotensin II antagonism of the detected compound.
    [42] The term "ester" includes "ester based on hydroxyl group" and "ester based on carboxyl group", wherein each ester moiety is a "protective group" which can be removed by a "general protecting group" or a biological method such as hydrolysis in vivo. ”Ester.
    [43] The term "general protecting group" refers to a protecting group that can be removed by chemical methods such as hydrogenolysis, hydrolysis, electrolysis and photolysis.
    [44] As the "general protecting group" related to "ester based on hydroxyl group", Preferably, formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, pivaloyl, valeryl, isovaleryl, octanoyl, Nonanoyl, decanoyl, 3-methylnonanoyl, 8-methylnonanoyl, 3-ethyloctanoyl, 3,7-dimethyloctanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl , Pentadecanoyl, hexadecanoyl, 1-methylpentadecanoyl, 14-methylpentadecanoyl, 13,13-dimethyltetradecanoyl, heptadecanoyl, 15-methylhexadecanoyl, octadecanoyl, 1-methyl Alkanoyl groups such as heptadecanoyl, nonadecanoyl, eicosanoyl, and hencosanoyl, halogenated alkylcarbonyl groups such as chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, and lower alkoxyalkylcarbonyl groups such as methoxyacetyl , Acryloyl, pro "Aliphatic acyl groups" such as unsaturated alkylcarbonyl groups such as oloyl, methacryloyl, crotonoyl, isocrotonoyl, and (E) -2-methyl-2-butenoyl (preferably having 1 to 6 carbon atoms) Lower aliphatic acyl groups); Arylcarbonyl groups such as benzoyl, α-naphthoyl, β-naphthoyl, halogenated arylcarbonyl groups such as 2-bromobenzoyl, 4-chlorobenzoyl, lower alkylated aryls such as 2,4,6-trimethylbenzoyl, 4-toluoyl Carbonyl group, lower alkoxylated arylcarbonyl group such as 4-anisoyl, nitrated arylcarbonyl group such as 4-nitrobenzoyl, 2-nitrobenzoyl, lower alkoxycarbonylated arylcarbonyl group such as 2- (methoxycarbonyl) benzoyl, 4 "Aromatic acyl groups" such as arylated arylcarbonyl groups such as -phenylbenzoyl; Lower alkoxycarbonyl groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, s-butoxycarbonyl, t-butoxycarbonyl, isobutoxycarbonyl, 2,2,2- "Alkoxycarbonyl groups" such as lower alkoxycarbonyl groups substituted with halogen or tri (lower alkyl) silyl groups such as trichloroethoxycarbonyl and 2-trimethylsilylethoxycarbonyl; Tetrahydropyran-2-yl, 3-bromotetrahydropyran-2-yl, 4-methoxytetrahydropyran-4-yl, tetrahydrothiopyran-2-yl, 4-methoxytetrahydrothiopyran- "Tetrahydropyranyl or tetrahydrothiopyranyl group" such as 4-yl; "Tetrahydrofuranyl or tetrahydrothiofuranyl groups" such as tetrahydrofuran-2-yl and tetrahydrothiofuran-2-yl; Tri (lower alkyl) silyl groups such as trimethylsilyl, triethylsilyl, isopropyldimethylsilyl, t-butyldimethylsilyl, methyldiisopropylsilyl, methyldi-t-butylsilyl, triisopropylsilyl, diphenylmethylsilyl "Silyl groups" such as tri (lower alkyl) silyl groups substituted with 1 to 2 aryl groups such as diphenylbutylsilyl, diphenylisopropylsilyl and phenyldiisopropylsilyl; (Lower alkoxy) methyl groups, such as methoxymethyl, 1,1-dimethyl-1-methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl, t-butoxymethyl, 2-methoxy "Alkoxymethyl groups" such as lower alkoxylated (lower alkoxy) methyl groups such as ethoxymethyl, halogeno (lower alkoxy) methyl such as 2,2,2-trichloroethoxymethyl and bis (2-chloroethoxy) methyl ; "Substituted ethyl groups" such as lower alkoxylated ethyl groups such as 1-ethoxyethyl and 1- (isopropoxy) ethyl, and halogenated ethyl groups such as 2,2,2-trichloroethyl; Lower alkyl groups substituted with 1 to 3 aryl groups such as benzyl, α-naphthylmethyl, β-naphthylmethyl, diphenylmethyl, triphenylmethyl, α-naphthyldiphenylmethyl, 9-anthrylmethyl, 4-methyl Benzyl, 2,4,6-trimethylbenzyl, 3,4,5-trimethylbenzyl, 4-methoxybenzyl, 4-methoxyphenyldiphenylmethyl, 2-nitrobenzyl, 4-nitrobenzyl, 4-chlorobenzyl, "Aralkyl groups" such as lower alkyl groups such as 4-bromobenzyl and 4-cyanobenzyl and lower alkyl groups substituted with 1 to 3 aryl groups substituted with aryl rings with lower alkyl, lower alkoxy, nitro, halogen, and cyano groups; "Alkenyloxycarbonyl groups" such as vinyloxycarbonyl and allyloxycarbonyl; 1-2 lower alkoxy or nitros such as benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl The "aralkyloxycarbonyl group" in which the aryl ring may be substituted by the group is mentioned.
    [45] As the "general protecting group" related to the "carboxyl group-based ester", Preferably, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2 Lower alkyl groups such as -dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl; Ethenyl, 1-propenyl, 2-propenyl, 1-methyl-2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, 2 -Ethyl-2-propenyl, 1-butenyl, 2-butenyl, 1-methyl-2-butenyl, 1-methyl-1-butenyl, 3-methyl-2-butenyl, 1-ethyl-2 -Butenyl, 3-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 1-ethyl-3-butenyl, 1-pentenyl, 2-pentenyl, 1-methyl- 2-pentenyl, 2-methyl-2-pentenyl, 3-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 4-pentenyl, 1-methyl-4-pentenyl Lower alkenyl groups such as 2-methyl-4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl; Ethynyl, 2-propynyl, 1-methyl-2-propynyl, 2-methyl-2-propynyl, 2-ethyl-2-propynyl, 2-butynyl, 1-methyl-2-butynyl, 2 -Methyl-2-butynyl, 1-ethyl-2-butynyl, 3-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 1-ethyl-3-butynyl, 2 -Pentynyl, 1-methyl-2-pentynyl, 2-methyl-2-pentynyl, 3-pentynyl, 1-methyl-3-pentynyl, 2-methyl-3-pentynyl, 4-pentynyl, Lower alkynyl groups such as 1-methyl-4-pentynyl, 2-methyl-4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl; Trifluoromethyl, trichloromethyl, difluoromethyl, dichloromethyl, dibromomethyl, fluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, 2-bro Halogeno such as moethyl, 2-chloroethyl, 2-fluoroethyl, 2-iodoethyl, 3-chloropropyl, 4-fluorobutyl, 6-iodohexyl, 2,2-dibromoethyl ( Lower alkyl) groups; Hydroxy ("lower alkyl group") such as 2-hydroxyethyl, 2,3-dihydroxypropyl, 3-hydroxypropyl, 3,4-dihydroxybutyl, 4-hydroxybutyl; "Lower aliphatic acyl"-"lower alkyl groups" such as acetylmethyl; Said "aralkyl group"; Said "silyl group" is mentioned.
    [46] The term “protecting group which can be removed by biological method such as hydrolysis in living body” refers to a protecting group that is removed by biological method such as hydrolysis in living body to produce a free acid or salt thereof. An experimental animal such as a mouse may be administered by intravenous injection or the like, and then the body fluids of the animal may be examined to determine the angiotensin II antagonism of the detected compound.
    [47] As the "protecting group which can be removed by biological methods such as hydrolysis in vivo" related to "hydroxyl-based ester", Preferably, formyloxymethyl, acetoxymethyl, dimethylaminoacetoxymethyl, propionyloxymethyl, Butyryloxymethyl, pivaloyloxymethyl, valeryloxymethyl, isovaleryloxymethyl, hexanoyloxymethyl, 1-formyloxyethyl, 1-acetoxyethyl, 1-propionyloxyethyl, 1-buty Ryloxyethyl, 1-pivaloyloxyethyl, 1-valeryloxyethyl, 1-isovaleryloxyethyl, 1-hexanoyloxyethyl, 1-formyloxypropyl, 1-acetoxypropyl, 1-propy Onyloxypropyl, 1-butyryloxypropyl, 1-pivaloyloxypropyl, 1-valeryloxypropyl, 1-isovaleryloxypropyl, 1-hexanoyloxypropyl, 1-acetoxybutyl, 1-propy Onyloxybutyl, 1-butyryloxybutyl, 1-pivaloyloxybutyl, 1-acetoxy 1-("lower aliphatic acyl" oxy)-"lower alkyl groups", such as yl, 1-propionyloxypentyl, 1-butyryloxypentyl, 1-pivaloyloxypentyl, 1-pivaloyloxyhexyl, cyclo Pentylcarbonyloxymethyl, cyclohexylcarbonyloxymethyl, 1-cyclopentylcarbonyloxyethyl, 1-cyclohexylcarbonyloxyethyl, 1-cyclopentylcarbonyloxypropyl, 1-cyclohexylcarbonyloxypropyl, 1 1-("cycloalkyl" carbonyloxy)-"lower alkyl group", such as -cyclopentylcarbonyloxybutyl, 1-cyclohexylcarbonyloxybutyl, 1-("aromatic acyl" oxy)-such as benzoyloxymethyl- 1- (acyloxy)-"lower alkyl group", such as a "lower alkyl group"; Methoxycarbonyloxymethyl, ethoxycarbonyloxymethyl, propoxycarbonyloxymethyl, isopropoxycarbonyloxymethyl, butoxycarbonyloxymethyl, isobutoxycarbonyloxymethyl, pentyloxycarbonyloxymethyl, Hexyloxycarbonyloxymethyl, cyclohexyloxycarbonyloxymethyl, cyclohexyloxycarbonyloxy (cyclohexyl) methyl, 1- (methoxycarbonyloxy) ethyl, 1- (ethoxycarbonyloxy) Ethyl, 1- (propoxycarbonyloxy) ethyl, 1- (isopropoxycarbonyloxy) ethyl, 1- (butoxycarbonyloxy) ethyl, 1- (isobutoxycarbonyloxy) ethyl, 1- ( t-butoxycarbonyloxy) ethyl, 1- (pentyloxycarbonyloxy) ethyl, 1- (hexyloxycarbonyloxy) ethyl, 1- (cyclopentyloxycarbonyloxy) ethyl, 1- (cyclopentyl Oxycarbonyloxy) propyl, 1- (cyclohexyloxycarbonyloxy) propyl, 1- (cyclopentyloxycarbonyloxy) butyl , 1- (cyclohexyloxycarbonyloxy) butyl, 1- (cyclohexyloxycarbonyloxy) ethyl, 1- (ethoxycarbonyloxy) propyl, 1- (methoxycarbonyloxy) propyl, 1 -(Ethoxycarbonyloxy) propyl, 1- (propoxycarbonyloxy) propyl, 1- (isopropoxycarbonyloxy) propyl, 1- (butoxycarbonyloxy) propyl, 1- (isobutoxycarbon Carbonyloxy) propyl, 1- (pentyloxycarbonyloxy) propyl, 1- (hexyloxycarbonyloxy) propyl, 1- (methoxycarbonyloxy) butyl, 1- (ethoxycarbonyloxy) butyl, 1- (propoxycarbonyloxy) butyl, 1- (isopropoxycarbonyloxy) butyl, 1- (butoxycarbonyloxy) butyl, 1- (isobutoxycarbonyloxy) butyl, 1- (methoxy (Lower alkoxycarbonyloxy) alkyl groups such as carbonyloxy) pentyl, 1- (ethoxycarbonyloxy) pentyl, 1- (methoxycarbonyloxy) hexyl, 1- (ethoxycarbonyloxy) hexyl; (5-phenyl-2-oxo-1,3-dioxolen-4-yl) methyl, [5- (4-methylphenyl) -2-oxo-1,3-dioxolen-4-yl] methyl, [5 -(4-methoxyphenyl) -2-oxo-1,3-dioxolen-4-yl] methyl, [5- (4-fluorophenyl) -2-oxo-1,3-dioxolene-4- Il] methyl, [5- (4-chlorophenyl) -2-oxo-1,3-dioxolen-4-yl] methyl, (2-oxo-1,3-dioxolen-4-yl) methyl, ( 5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl, (5-ethyl-2-oxo-1,3-dioxolen-4-yl) methyl, (5-propyl-2- Oxo-1,3-dioxolen-4-yl) methyl, (5-isopropyl-2-oxo-1,3-dioxolen-4-yl) methyl, (5-butyl-2-oxo-1,3 Oxodioxorenylmethyl groups such as -dioxolen-4-yl) methyl; "Carbonyloxyalkyl groups" such as these; "Phthalidyl groups" such as phthalidyl, dimethylphthalidyl and dimethoxyphthalidyl; Said "lower aliphatic acyl group"; Said "aromatic acyl group"; "Half ester salt residue of succinic acid": "Phosphate ester salt residue": "Ester forming residues, such as amino acid": Carbamoyl group: Carbamoyl group substituted by 1-2 lower alkyl groups: and pivaloyloxymethyloxycar "1- (acyloxy) alkyloxycarbonyl group" like carbonyl is mentioned, Preferably it is "carbonyloxyalkyl group".
    [48] On the other hand, as the "protecting group which can be removed by biological methods such as hydrolysis in vivo" related to "ester based on carboxyl group", Preferably it is methoxymethyl, 1-ethoxyethyl, 1-methyl-1-methoxy Ethyl, 1- (isopropoxy) ethyl, 2-methoxyethyl, 2-ethoxyethyl, 1,1-dimethyl-1-methoxymethyl, ethoxymethyl, n-propoxymethyl, isopropoxymethyl, (lower alkoxy) (lower alkyl) groups such as n-butoxymethyl, t-butoxymethyl, lower alkoxylated (lower alkoxy) (lower alkyl) groups such as 2-methoxyethoxymethyl, phenoxymethyl "Alkoxy (lower alkyl) groups, such as halogenated (lower alkoxy) (lower alkyl) groups such as" aryl "oxy (" lower alkyl group "), 2,2,2-trichloroethoxymethyl and bis (2-chloroethoxy) methyl Alkyl) group ”; "Lower alkoxy" carbonyl "lower alkyl groups" such as methoxycarbonylmethyl; "Cyano" lower alkyl group "such as cyanomethyl and 2-cyanoethyl; "Lower alkyl" thiomethyl groups such as methylthiomethyl and ethylthiomethyl; "Aryl" thiomethyl groups such as phenylthiomethyl and naphthylthiomethyl; "Lower alkyl" sulfonyl "lower alkyl group" which may be substituted with halogen such as 2-methanesulfonylethyl and 2-trifluoromethanesulfonylethyl; "" Aryl "sulfonyl" lower alkyl group "such as 2-benzenesulfonylethyl and 2-toluenesulfonylethyl; Said "1- (acyloxy)-" lower alkyl "group; Said "phthalidyl group"; Aryl groups such as phenyl and indanyl; Said "lower alkyl group"; "Carboxyalkyl groups" such as carboxymethyl; And "amide forming residues such as amino acids" such as phenylalanine.
    [49] "Other derivative" means derivatives other than said "ester" and "pharmacologically acceptable salt" which may be formed when the compound I of this invention has an amino group and / or a carboxyl group. Examples of such derivatives include amide derivatives.
    [50] Embodiment of the invention
    [51] In the prophylactic and therapeutic agent for glaucoma of the present invention, angiotensin II antagonists disclosed, for example, in EP795326, EP631780, WO 95/21609, WO 91/15206 and the like can be adopted, and these compounds can be easily prepared according to known methods.
    [52] As the "adrenergic receptor blocker", for example, compounds disclosed in GB 1253710, GB 1398455, EP 42299 and the like can be adopted, and these compounds can be easily produced according to known methods.
    [53] As "prostaglandins", for example, compounds disclosed in EP 289349 and WO 90/2553 can be adopted, and these compounds can be easily produced according to known methods.
    [54] As the "carbonate dehydratase inhibitor", for example, compounds disclosed in EP 296879 can be adopted, and these compounds can be easily prepared according to known methods.
    [55] In the prophylactic and therapeutic agent for glaucoma of the present invention, a pharmaceutical composition for simultaneously using at least one compound selected from angiotensin II antagonists, adrenergic receptor blockers, prostaglandins, and carbonic anhydrase inhibitors, is a compound that is an active ingredient (ie, angiotensin II antagonist). And one or more compounds selected from adrenergic receptor blockers, prostaglandins and carbonic anhydrase inhibitors), and may be prepared according to conventional methods, preferably aqueous eye drops, aqueous suspension eye drops, non-aqueous eye drops and non-aqueous suspension eye drops. Such as eye drops, gels, eye ointments, etc., in a form suitable for topical administration to the eye. In preparing such a formulation, a pharmacologically acceptable carrier can be used. The carrier to be used is not particularly limited as long as it is used for the preparation of a formulation normally applied to the eye, and examples thereof include inert diluents, preservatives, isotonic agents, buffers, stabilizers, pH adjusters, thickeners, surfactants, and ointments. have.
    [56] Examples of the inert diluent include an aqueous solvent such as water, ring gel solution, isotonic saline solution, castor oil, olive oil, sesame oil, soybean oil, oily solvent such as liquid paraffin, propylene glycol, β-octyldodecanol, and the like.
    [57] Examples of the preservative include parabens such as methyl paraben, ethyl paraben, propyl paraben and butyl paraben, benzalkonium chloride, chlorhexidine, benzogenium chloride, benzyl alcohol, sorbic acid and its salts, thimerosal and chlorobutanol. Preferably, parabens, benzalkonium chloride, and benzethonium chloride are used.
    [58] Examples of the tonicity agent include sodium chloride, mannitol, sorbitol, glycerin, and the like.
    [59] Examples of the buffer include boric acid, borate, phosphate, acetate, citrate and the like.
    [60] Ethylenediamine tetraacetic acid salt etc. are mentioned as a stabilizer.
    [61] Examples of pH adjusters include hydrochloric acid, acetic acid and sodium hydroxide.
    [62] Examples of the ointment include petrolatum, plastibase, liquid paraffin, and the like.
    [63] Examples of the thickener include methyl cellulose, carmellose and salts thereof, hydroxyethyl cellulose, sodium alginate, carboxyvinyl polymer, and polyvinylpyrrolidone.
    [64] Examples of the surfactant include polyethylene glycol, propylene glycol, polyoxyethylene hardened castor oil, and polysorbate.
    [65] When preparing a gel, for example, a carboxyvinyl polymer, methyl cellulose, sodium arginate, hydroxypropyl cellulose, ethylene maleic anhydride polymer, or the like can be used.
    [66] The pharmaceutical composition may contain each compound serving as an active ingredient at a concentration of 0.001% (preferably 0.01%) as the lower limit and 10% (preferably 5%) as the upper limit.
    [67] The dosage of the pharmaceutical composition varies depending on the symptom and the like, but, for example, when used as an eye drop, one to several drops, preferably one or two drops (about 50 µl of one drop) per day, may be It may be administered about six times.
    [68] The pharmaceutical composition may also be prepared in a form suitable for oral administration such as tablets, capsules, granules, powders or syrups, or in a form suitable for parenteral administration by injection or suppository. These formulations include excipients (e.g. sugar derivatives such as lactose, white sugar, glucose, mannitol, sorbitol; starch derivatives such as corn starch, potato starch, α-starch, dextrin, carboxymethyl starch; crystalline cellulose, low-substituted hydroxypropyl). Cellulose derivatives such as cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium, internally crosslinked carboxymethyl cellulose sodium; organic excipients such as gum araba (acac1a), dextran, pullulan: and hard silicic anhydride, synthetic Silicate derivatives such as aluminum silicate and magnesium metasilicate; phosphates such as calcium phosphate; carbonates such as calcium carbonate; inorganic excipients such as sulfates such as calcium sulfate), lubricants (e.g., stearic acid, calcium stearate) Metal stearate salts such as magnesium stearate; Talc, colloidal silica; waxes such as beeswax and sperm; boric acid; sulfates such as adipic acid and sodium sulfate; glycol, fumaric acid, sodium benzoate; DL leucine; fatty acid sodium salts; sodium lauryl sulfate, lauryl magnesium sulfate Sulfates; silicic acids such as silicic anhydrides, silicic acid hydrates; and starch derivatives mentioned above, binders (e.g., polyvinylpyrrolidone, macrogol, and compounds similar to the above excipients), disintegrants (e.g. , Compounds similar to the above excipients, and chemically modified starch celluloses such as croscarmellose sodium, carboxymethyl starch sodium, crosslinked polyvinylpyrrolidone), stabilizers (methyl parabens, propyl parabens such as propylparabens) Benzoic acid esters; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; phenols such as phenol and cresol; thimerosal Dehydroacetic acid; and sorbic acid), a colloidal agent (e.g., commonly used sweeteners, acidulants, fragrances, etc.), diluents and the like are prepared by known methods.
    [69] The amount of use varies depending on the symptoms, age, administration method, etc. In the case of oral administration, for example, the lower limit per dose is 0.01 mg / kg body weight (preferably 0.1 mg / kg body weight), and the upper limit is 100 mg / kg body weight (preferably). 50 mg / kg body weight); In the case of intravenous administration, each active ingredient of 0.01 mg / kg body weight (preferably 0.05 mg / kg body weight) at the lower limit and 100 mg / kg body weight (preferably 50 mg / kg body weight) at the upper limit is symptomatic. In some cases, it is preferable to administer once to several times per day.
    [70] Meanwhile, in the prophylactic and therapeutic agent for glaucoma of the present invention, a pharmaceutical composition for separately or sequentially using one or more compounds selected from angiotensin II antagonists, adrenergic receptor blockers, prostaglandins, and carbonic anhydrase inhibitors, each compound (ie, an active ingredient) , Angiotensin II antagonists and one or more compounds selected from adrenergic receptor blockers, prostaglandins and carbonic anhydrase inhibitors), and the formulation can be carried out according to the above method. At this time, each formulation may be the same shape or different shapes, but it is particularly preferable that each formulation is a shape suitable for topical administration to the eye.
    [71] Best Mode for Carrying Out the Invention
    [72] Next, the present invention will be described in more detail with reference to Examples, but the present invention is not limited thereto.
    [73] Example 1
    [74] New Zealand white rabbits, weighing 2-3 kg, were used and Kurihara et al. [Jpn. J. Ocular Pharmacology, 4, 62-64 (1990)], to prepare a model of intraocular pressure elevation to examine the effect of intraocular pressure on the test compound.
    [75] That is, rabbits are general anesthetized and the intraocular pressure is measured by an tonometer (Alcon Applanation Pneumatonography, manufactured by Alcon). Subsequently, a topical anesthetic is applied to the rabbit eye, and then 0.1 ml of 5% sodium chloride solution is injected into the vitreous through a 30 gauge needle. After 30 minutes of injection, it was confirmed that the intraocular pressure had risen, and 50 µl of an eye drop containing the test compound was used. Then, intraocular pressure is measured for 2 hours at 30 minute intervals (alone administration test).
    [76] Similarly, after confirming the elevation of the intraocular pressure in the use administration test, 50 μl of the first test drug was applied, and after 5 minutes, the second test drug was applied in the same amount, and intraocular pressure was measured for 2 hours at an interval of 30 minutes thereafter. .
    [77] In addition, about the following compound A, it melt | dissolves in a suitable amount of sodium hydroxide aqueous solution, and uses this as a test agent. For the following Compounds B to E, commercially available eye drops are used as the test agent.
    [78] Compound A:
    [79] Compound B: Maleic Acid Timolol
    [80] Compound C: Isopropyl Unoprostone
    [81] Compound D: Ratanoprost
    [82] Compound E: Dorzolamide Hydrochloride
    [83] Intraocular pressure lowering action was enhanced by co-administration of Compound A and Compound B, C, D, or E which are angiotensin II antagonists.
    [84] Example 2 Intraocular Pressure Lowering Action (2)
    [85] After measuring the intraocular pressure of New Zealand white rabbit (without anesthesia) weighing 2 to 3 kg with an tonometer (Alcon Applanation Pneumatonography, manufactured by Alcon), 50 μl of the test drug was instilled. Then, intraocular pressure is measured for 4 hours at 1 hour intervals (alone administration test).
    [86] In the combined administration test, the intraocular pressure before instillation was similarly measured, followed by 50 μl of the first test drug, and after 5 minutes, the second test drug was applied in the same amount, and then the intraocular pressure was measured for 1 hour at 4 hour intervals. do.
    [87] In addition, also in the present Example, the same test body as described in Example 1 is used.
    [88] Intraocular pressure lowering action was enhanced by co-administration of Compound A and Compound B, C, D, or E which are angiotensin II antagonists.
    [89] Example 3 Intraocular Pressure Reduction Test (3)
    [90] After measuring the intraocular pressure in the same manner as in Example 2, 50 μl of Test 1 was applied, and after 5 minutes, Topic 2 was applied in the same amount, and intraocular pressure was measured 4 hours after that time. Obtain:
    [91] Intraocular pressure change rate (%) = [(Intraocular pressure after eye drop-intraocular pressure) / intraocular pressure before eye drop] × 100
    [92] In addition, also in the present Example, the same test body as described in Example 1 is used. The results are shown in Tables 1 and 2 below.
    [93] Combination of Compound A and Compound C Test drug 1Test Medicine 2Intraocular pressure change rate (%) Physiological SalinePhysiological Saline7.3 ± 3.7 Compound A (4%)Physiological Saline11.4 ± 5.5 Physiological SalineCompound C (0.12%)-2.4 ± 9.1 Compound A (4%)Compound C (0.12%)-15.3 ± 4.5
    [94] Combination of Compound A and Compound D Test drug 1Test Medicine 2Intraocular pressure change rate (%) Physiological SalinePhysiological Saline1.7 ± 4.4 Compound A (4%)Physiological Saline11.5 ± 4.1 Physiological SalineCompound D (0.005%)17.2 ± 8.8 Compound A (4%)Compound D (0.005%)-8.2 ± 4.7
    [95] As can be seen from Table 1 and Table 2, synergistic intraocular pressure-lowering effect was observed when angiotensin II antagonist (Compound A) and prostaglandins (Compound C, Compound D) were administered in combination.
    [96] Example 4 Intraocular Pressure Reduction Test (4)
    [97] In the same manner as in Example 1, an intraocular pressure elevation model was prepared, and after confirming that the intraocular pressure was elevated, eye drops of 50 μl of Test 1 were applied, and after 5 minutes, the amount of Test 2 was applied in the same amount. Intraocular pressure is measured during time, and the drop in intraocular pressure is calculated by the following equation.
    [98] Intraocular pressure drop width (mmHg) = (intraocular pressure before instillation of intraocular pressure-drug group after instillation of drug group)-(intraocular pressure before instillation of intraocular pressure-control group after instillation of control group)
    [99] However, in the above formula, the "control group" refers to a group in which physiological saline is instilled in place of each of the test drug 1 and the test drug 2, and the other group is a drug group.
    [100] In addition, also in the present Example, the same test body as described in Example 1 is used. The results are shown in Table 3 below.
    [101] Combination of Compound A and Compound B Test drug 1Test Medicine 2Intraocular pressure drop (mmHg) [time after eye drop (minutes)] 060120 Physiological SalinePhysiological Saline000 Compound A (1%)Physiological Saline0.0 ± 2.1-1.7 ± 2.2-3.4 ± 1.7 Physiological SalineCompound B (0.25%)0.0 ± 1.5-2.0 ± 3.5-1.9 ± 3.2 Compound A (1%)Compound B (0.25%)0.0 ± 0.9-5.0 ± 2.4-7.4 ± 1.8
    [102] As can be seen from Table 3, when angiotensin II antagonist (Compound A) and maleic acid timolol (Compound B) were administered in combination, a stronger intraocular pressure lowering effect was observed.
    [103] [Example]
    [104] Preparation Example 1 Eye drops containing Compound A and maleic acid timolol
    [105] Compound A Timorol Dibasic Sodium Phosphate Monosodium Phosphate Sodium Chloride p-Hydroxybenzoate Methyl p-Hydroxybenzoic Acid Propylated Purified Sodium Hydroxide0.001g0.001g0.716g0.728g0.400g0.026g0.014g Total100 ml
    [106] Preparation Example 2 Combination of Eye Drop of Compound A and Eye Drop of Isopropyl Unoprostone
    [107] Compound A Sodium Phosphate Sodium Phosphate Sodium Chloride p-Hydroxybenzoate Methyl p-Hydroxybenzoic Acid Propylated Purified Sodium Hydroxide0.002 g 0.716 g 0.728 g 0.400 g 0.026 g 0.014 g Total100 ml
    [108] Isopropyl Unoprostone Phosphate Dibasic Sodium Phosphate Sodium Chloride p-Hydroxybenzoate Methyl p-Hydroxybenzoic Acid Propylated Purified Sodium Hydroxide0.002 g 0.716 g 0.728 g 0.400 g 0.026 g 0.014 g Total100 ml
    [109] Preparation Example 3 Combination of Eye Drop of Compound A and Eye Drop of Latanoprost
    [110] Compound A Sodium Phosphate Sodium Phosphate Sodium Chloride p-Hydroxybenzoate Methyl p-Hydroxybenzoic Acid Propylated Purified Sodium Hydroxide0.002 g 0.716 g 0.728 g 0.400 g 0.026 g 0.014 g Total100 ml
    [111] Sodium Hydroxanthrate Sodium Phosphate Sodium Phosphate Sodium Chloride p-Hydroxybenzoate Methyl p-Hydroxybenzoic Acid Propylated Purified Sodium Hydroxide0.002 g 0.716 g 0.728 g 0.400 g 0.026 g 0.014 g Total100 ml
    [112] By using an angiotensin II antagonist and at least one compound selected from an adrenergic receptor blocker, prostaglandins and carbonic anhydrase inhibitors, an excellent intraocular pressure lowering effect can be obtained. That is, the pharmaceutical composition of the present invention is useful as a prophylactic or therapeutic agent for glaucoma.
    权利要求:
    Claims (4)
    [1" claim-type="Currently amended] As a prophylactic or therapeutic agent for glaucoma containing angiotensin II antagonist and maleic acid timolol simultaneously, separately or sequentially, as an active ingredient,
    A prophylactic or therapeutic agent for glaucoma, wherein said angiotensin II antagonist is a compound having the formula: or a pharmacologically acceptable salt, ester, or other derivative thereof:
    [Formula 1]
    [Wherein, R 1 is the following structural formula (1a):

    Group with
    [2" claim-type="Currently amended] The agent for preventing or treating glaucoma according to claim 1, which is in a form suitable for topical administration to the eye.
    [3" claim-type="Currently amended] As a method of using angiotensin II antagonist together with maleic acid timolol in the manufacture of a medicament for preventing or treating glaucoma, simultaneously or separately,
    Wherein said angiotensin II antagonist is a compound of Formula 1 or a pharmacologically acceptable salt, ester or other derivative thereof:
    [Formula 1]
    [Wherein, R 1 is the following structural formula (1a):

    Group with
    [4" claim-type="Currently amended] 4. The method of claim 3, wherein the medicament is in a shape suitable for topical administration to the eye.
    类似技术:
    公开号 | 公开日 | 专利标题
    US8053431B2|2011-11-08|Pharmaceutical use of substituted amides
    EP1372649B1|2012-07-25|Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
    EP1933833B1|2011-04-20|Therapy for the treatment of overactive bladder
    JP3874419B2|2007-01-31|Pharmaceuticals for the prevention and treatment of arteriosclerosis and hypertension
    CA2502437C|2012-07-17|Method and composition containing latanoprost for treating ocular hypertension and glaucoma
    CN1133434C|2004-01-07|Cyclopentane heptan| oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
    US5942251A|1999-08-24|Pharmaceutical compositions for intranasal administration of dihydroergotamine
    EP0831832B1|2003-12-17|Methods of combatting infectious diseases using dicationic bis-benzimidazoles
    KR100810872B1|2008-03-06|Compositions for treatment of common cold
    ES2646326T3|2017-12-13|Use of flibanserin in the treatment of obesity
    US6410591B1|2002-06-25|3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
    US8084445B2|2011-12-27|Pharmaceutical formulation
    JP5148296B2|2013-02-20|Angiotensin II receptor antagonist and pharmaceutical composition containing calcium antagonist
    KR101160780B1|2012-06-27|REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
    KR100656716B1|2006-12-13|Medicinal compositions
    RU2188013C2|2002-08-27|Combination containing a compound of angiotensin ii-antagonistic activity
    US6767920B2|2004-07-27|3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
    JP2965704B2|1999-10-18|Oral composition containing ondansetron
    ES2377975T3|2012-04-03|Medicinal composition comprising an HMG-CoA reductase inhibitor and an amino alcohol derivative as an immunosuppressant
    US5462726A|1995-10-31|Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
    US5393773A|1995-02-28|Method for the intranasal administration of 3-[2-|-ethyl]-H-methyl-1H-indole-5-methanesulphonamide
    US20040024007A1|2004-02-05|Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
    US20070128125A1|2007-06-07|Pharmaceutical Compositions Based on Tiotropium Salts and Salts of Salmeterol
    US20040110747A1|2004-06-10|Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
    AU772406B2|2004-04-29|Use of H1 antagonist and a safe steroid to treat eye conditions
    同族专利:
    公开号 | 公开日
    IL149444A|2007-06-17|
    US20080221184A1|2008-09-11|
    DE60029242T2|2007-07-05|
    KR100607430B1|2006-08-02|
    BR0015980A|2002-11-12|
    DE60029242D1|2006-08-17|
    TWI290470B|2007-12-01|
    CA2392804C|2009-02-03|
    HU0204049A2|2003-04-28|
    CA2392804A1|2001-06-07|
    RU2004111358A|2005-09-20|
    JP2001335511A|2001-12-04|
    EP1234582B1|2006-07-05|
    US20030040529A1|2003-02-27|
    CN1615880A|2005-05-18|
    US7307096B2|2007-12-11|
    HU0204049A3|2006-07-28|
    NZ518930A|2003-09-26|
    US20050043383A1|2005-02-24|
    ES2267586T3|2007-03-16|
    EP1234582A1|2002-08-28|
    RU2004111357A|2005-09-20|
    AU773110B2|2004-05-20|
    AU1557501A|2001-06-12|
    PL355431A1|2004-04-19|
    IL149444D0|2002-11-10|
    CZ20021829A3|2002-08-14|
    EP1344535A2|2003-09-17|
    WO2001039805A1|2001-06-07|
    PL201783B1|2009-05-29|
    CN1263512C|2006-07-12|
    KR20040045028A|2004-05-31|
    RU2004111359A|2005-09-20|
    RU2002114335A|2004-01-10|
    EP1344534A2|2003-09-17|
    CN1407903A|2003-04-02|
    RU2299067C2|2007-05-20|
    KR20020058034A|2002-07-12|
    AT332145T|2006-07-15|
    EP1344535A3|2004-01-28|
    US20050014808A1|2005-01-20|
    CN1615879A|2005-05-18|
    HK1047239A1|2006-12-08|
    MXPA02005505A|2002-09-02|
    HK1047239B|2006-12-08|
    EP1344534A3|2004-01-02|
    JP4000505B2|2007-10-31|
    EP1234582A4|2003-05-07|
    NO20022584D0|2002-05-31|
    NO20022584L|2002-07-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    1999-12-01|Priority to JPJP-P-1999-00341524
    1999-12-01|Priority to JP34152499
    2000-03-21|Priority to JP2000078769
    2000-03-21|Priority to JPJP-P-2000-00078769
    2000-12-01|Application filed by 상꾜 가부시키가이샤
    2000-12-01|Priority to PCT/JP2000/008545
    2004-05-31|Publication of KR20040045029A
    优先权:
    申请号 | 申请日 | 专利标题
    JPJP-P-1999-00341524|1999-12-01|
    JP34152499|1999-12-01|
    JP2000078769|2000-03-21|
    JPJP-P-2000-00078769|2000-03-21|
    PCT/JP2000/008545|WO2001039805A1|1999-12-01|2000-12-01|Concomitant drugs for treating glaucoma|
    [返回顶部]